PE20070238A1 - Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas - Google Patents

Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas

Info

Publication number
PE20070238A1
PE20070238A1 PE2006000891A PE2006000891A PE20070238A1 PE 20070238 A1 PE20070238 A1 PE 20070238A1 PE 2006000891 A PE2006000891 A PE 2006000891A PE 2006000891 A PE2006000891 A PE 2006000891A PE 20070238 A1 PE20070238 A1 PE 20070238A1
Authority
PE
Peru
Prior art keywords
compound
formula
same
chiral agent
agonists
Prior art date
Application number
PE2006000891A
Other languages
English (en)
Inventor
Sreenivasulu Megati
Anita Wai-Yin Chan
Gregg B Feigelson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070238A1 publication Critical patent/PE20070238A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN METODO PARA PREPARAR UN COMPUESTO DE FORMULA (II) QUE CONSISTE EN: (a) PROPORCIONAR UN COMPUESTO DE FORMULA E, (b) TRATAR DICHO COMPUESTO E CON UN AGENTE QUIRAL PARA FORMAR UN COMPUESTO DE FORMULA D-1, (c) OBTENER UN COMPUESTO DE FORMULA D POR MEDIOS FISICOS ADECUADOS, (d) TRATAR EL COMPUESTO D CON UNA BASE ADECUADA PARA PROPORCIONAR UN COMPUESTO DE FORMULA C, (e) ALQUILAR EL COMPUESTO C PARA FORMAR UN COMPUESTO B, (f) DESPROTEGER EL COMPUESTO B PARA FORMAR UN COMPUESTO A Y (g) HACER REACCIONAR EL COMPUESTO A CON FORMALDEHIDO O UN EQUIVALENTE DEL MISMO, PARA FORMAR UN COMPUESTO DE FORMULA (II); DONDE n ES 0, 1, 2; R1 Y R2 SON HALOGENO, CN, FENILO, ENTRE OTROS; R ES H O ALQUILO C1-C6; R7 ES H; X ES UN AGENTE QUIRAL TAL COMO ACIDO TARTARICO, ACIDO MANDELICO, ACIDO MALICO, ENTRE OTROS; PG2 ES UN GRUPO AMINO PROTECTOR ADECUADO TALES COMO BENCILO, FENILACETILO, ALILO, ENTRE OTROS. DICHO PROCEDIMIENTO PROPORCIONA COMPUESTOS QUE TIENEN ACTIVIDAD COMO AGONISTAS O AGONISTAS PARCIALES DE LOS RECEPTORES DE SEROTONINA (5HT2C) Y SON UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, DESORDEN ESQUIZOFRENIFORME, DEMENCIA, EPILEPSIA, ENTRE OTROS
PE2006000891A 2005-07-26 2006-07-24 Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas PE20070238A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70250905P 2005-07-26 2005-07-26

Publications (1)

Publication Number Publication Date
PE20070238A1 true PE20070238A1 (es) 2007-03-26

Family

ID=37603396

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000891A PE20070238A1 (es) 2005-07-26 2006-07-24 Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas

Country Status (20)

Country Link
US (1) US7671196B2 (es)
EP (1) EP1907390A2 (es)
JP (1) JP2009502925A (es)
KR (1) KR20080030682A (es)
CN (1) CN101268076A (es)
AR (1) AR054849A1 (es)
AU (1) AU2006276010A1 (es)
BR (1) BRPI0614154A2 (es)
CA (1) CA2616161A1 (es)
CR (1) CR9670A (es)
EC (1) ECSP088151A (es)
GT (1) GT200600326A (es)
IL (1) IL188896A0 (es)
MX (1) MX2008001030A (es)
NO (1) NO20080468L (es)
PE (1) PE20070238A1 (es)
RU (1) RU2008102884A (es)
SA (1) SA06270241B1 (es)
TW (1) TW200738713A (es)
WO (1) WO2007016029A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
WO2007112073A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
AR060088A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
WO2007112000A2 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
CN103204858A (zh) * 2013-03-20 2013-07-17 广州科瑞生物技术有限公司 基于酒石酸拆分合成工艺制备新型手性抗焦虑症药物

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120461A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
SU930902A1 (ru) 1980-12-18 1982-10-15 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные тиено [3,2=в] индола
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
US4948897A (en) * 1987-12-11 1990-08-14 Jet Research Center, Inc. Method of preparation of 2,6-bis(picrylamino)-3,5-dinitropyridine
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH0240379A (ja) 1988-07-28 1990-02-09 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体
EP0357417A1 (en) 1988-09-01 1990-03-07 Glaxo Group Limited Lactam derivatives
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
CN1104418C (zh) * 1994-06-15 2003-04-02 大塚制药株式会社 苯并杂环衍生物
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
JPH10237073A (ja) 1996-02-02 1998-09-08 Sumitomo Pharmaceut Co Ltd 新規な置換グアニジン誘導体およびその製法
CA2195697A1 (en) * 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
WO1997030999A1 (en) 1996-02-21 1997-08-28 Darwin Discovery Limited Quinolones and their therapeutic use
WO1997031000A1 (en) 1996-02-21 1997-08-28 Darwin Discovery Limited Quinolones and their therapeutic use
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6194407B1 (en) * 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6031098A (en) * 1997-08-11 2000-02-29 California Institute Of Technology Detection and treatment of duplex polynucleotide damage
DE19806348A1 (de) 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
WO1999067219A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2002518451A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド 環状アミノ酸化合物およびその医薬組成物、並びにそれら化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
BR9916326A (pt) 1998-12-17 2001-10-02 American Home Prod Derivados de 2,3,4,4a-tetrahidro-1h-pirazino(1,2-a)quinoxalin-5-(6h) ona sendo agonistas de 5ht2c
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
KR100722090B1 (ko) 1999-05-21 2007-05-25 바이오비트럼 에이비 신규 화합물, 이의 용도 및 이의 제조 방법
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
ES2228549T3 (es) 1999-06-15 2005-04-16 Bristol-Myers Squibb Pharma Company Gamma-carbolinas condensadas con heterociclo sustituido.
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
JP2001089461A (ja) 1999-09-24 2001-04-03 Konica Corp テトラヒドロナフトジアゼピン類の製造方法及びスクアリリウム染料の製造方法
CA2397349A1 (en) 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with an her2 antibody
JP2001244249A (ja) * 2000-03-01 2001-09-07 Speedfam Co Ltd 局部エッチング装置の放電管及びテーパ型放電管を用いた局部エッチング装置
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US6759405B2 (en) * 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6503900B2 (en) * 2000-11-03 2003-01-07 Wyeth [1,4]diazepino [6,7,1-jk ]carbazoles and derivatives
AR031197A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR031198A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
ATE280170T1 (de) 2000-11-03 2004-11-15 Wyeth Corp Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indole als 5ht2c antagonisten
US6916922B2 (en) * 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
US6784172B2 (en) * 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) * 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AU2002227170A1 (en) 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
HUP0303530A3 (en) * 2000-12-20 2012-10-29 Bristol Myers Squibb Co Stituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists and pharmaceutical compositions containing them
WO2002059129A2 (en) * 2000-12-20 2002-08-01 Bristol-Myers Squibb Company Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) * 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
JP2005501092A (ja) * 2001-08-06 2005-01-13 ファルマシア・アンド・アップジョン・カンパニー 治療上有用な四環リガンド
EP1436294A1 (en) * 2001-10-18 2004-07-14 PHARMACIA & UPJOHN COMPANY Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
SE0201544D0 (sv) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
WO2004072046A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivatives and their use for modulation of lxr activity
EP1618102B1 (en) 2003-04-21 2010-02-10 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
MXPA06002504A (es) 2003-09-04 2006-06-20 Lundbeck & Co As H Combinacion de un inhibidor de recaptacion de serotonina y loxapina.
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
TW200635926A (en) * 2004-11-05 2006-10-16 Wyeth Corp Metabolites of ceratin [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof
EP1714963A1 (en) 2005-04-19 2006-10-25 IPCA Laboratories Limited Process for the Preparation of Valsartan and its Intermediates
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
PE20070549A1 (es) * 2005-10-17 2007-06-15 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
WO2007112073A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
EP1998780A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware New therapeutic combinations for the treatment or prevention of psychotic disorders
AR060088A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
WO2007112000A2 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.

Also Published As

Publication number Publication date
IL188896A0 (en) 2008-04-13
BRPI0614154A2 (pt) 2011-03-15
MX2008001030A (es) 2008-03-19
WO2007016029A2 (en) 2007-02-08
GT200600326A (es) 2007-03-14
RU2008102884A (ru) 2009-09-10
US7671196B2 (en) 2010-03-02
ECSP088151A (es) 2008-02-20
KR20080030682A (ko) 2008-04-04
AR054849A1 (es) 2007-07-18
EP1907390A2 (en) 2008-04-09
WO2007016029A3 (en) 2007-05-18
CA2616161A1 (en) 2007-02-08
SA06270241B1 (ar) 2009-09-02
CR9670A (es) 2008-07-29
TW200738713A (en) 2007-10-16
JP2009502925A (ja) 2009-01-29
US20070027142A1 (en) 2007-02-01
AU2006276010A1 (en) 2007-02-08
NO20080468L (no) 2008-02-22
CN101268076A (zh) 2008-09-17

Similar Documents

Publication Publication Date Title
PE20070238A1 (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
CL2018000036A1 (es) Derivados etinilo
AR102467A1 (es) Métodos para tratar infecciones por el virus filoviridae
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
AR061067A1 (es) Coterapeutica para el tratamiento de epilepsia y trastornos relacionados
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112012022910A2 (pt) inibidores de pde10 e composições e métodos relacionados
ECSP045073A (es) Nuevos derivados de piperazina
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
PE20110383A1 (es) Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
CL2012000001A1 (es) Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros.
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PA8501801A1 (es) Inhibidores triciclicos de polimerasas (adp - polirribosas)
PE20070041A1 (es) Amidas de acido pirazolcarboxilico
PE20110588A1 (es) Derivados de benzotiazol como agentes anticancerigenos
ECSP066415A (es) 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas
RU2012155118A (ru) Способы лечения биполярного расстройства
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
PH12018502457B1 (en) Treatment for parkinson's disease
AR052175A1 (es) Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos

Legal Events

Date Code Title Description
FX Voluntary withdrawal